BOCA RATON, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) — NOMAD Power Solutions, Inc. (“NOMAD” or the “Company”) (Nasdaq: NMAD) (formerly LIXTE Biotechnology Holdings), a provider of transportable, utility-grade battery energy storage systems through its wholly owned subsidiary NOMAD Transportable Power Systems, today announced that its Special Meeting of Stockholders (the “Special Meeting”), reconvened on October 2, 2026, was adjourned without conducting any business. The Special Meeting will reconvene on October 30, 2026, at 1:00 PM Eastern Time.

The adjournment provides the Company additional time to finalize its Nasdaq listing filing in connection with the previously completed merger with NOMAD Transportable Power Systems.

No changes have been made to the proposals to be voted on at the Special Meeting. The Board of Directors continues to recommend that stockholders vote “FOR” the proposals. Stockholders who have already submitted their proxies and do not wish to change their votes need not take any further action.

The reconvened Special Meeting will be held virtually at www.virtualshareholdermeeting.com/NMAD2026SM.

The Company’s proxy statement and any other materials filed by the Company with the SEC can be obtained free of charge at the SEC’s website at www.sec.gov.

About NOMAD Power Solutions, Inc.

NOMAD Power Solutions, Inc., through its wholly owned subsidiary NOMAD Transportable Power Systems, provides transportable, utility-grade battery energy storage systems. The company’s mobile battery energy storage system (BESS) platforms deliver rapidly deployable, scalable energy solutions for electric utilities, data centers, commercial and industrial customers, emergency response, renewable energy integration, and grid modernization. By mobilizing energy storage, NOMAD enables customers to deploy power where and when it is needed without waiting for permanent infrastructure.

For more information, please visit https://ir.nomadpower.com/.

# # #

Investor and Media Contact:

PondelWilkinson pwinvestor@pondel.com

Todd Kehrli: (310) 279-5961; tkehrli@pondel.com
Michael Wichman: (917) 526-0855; mwichman@pondel.com

TORONTO, Oct. 02, 2026 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) reported on its capital markets activity for the previous quarter, including activity under its at-the-market equity program (“ATM”) and equity participation by employees and directors.

The Company’s equity participation programs support alignment between employees, directors and shareholders through market-based equity ownership. Under the Company’s Employee Share Purchase Program (“ESP”), a total of 37,341 common shares (“Common Shares”) were purchased by employees during the third quarter, with a corresponding 37,341 Common Shares acquired by the Company in accordance with the program. Employee participation included meaningful purchases by Company management. Approved by shareholders at the Company’s annual general meeting on June 23, 2026, the ESP enables employees to acquire Common Shares. Purchases were made at the five-day volume-weighted average price as of September 30, 2026.

On September 30, 2026, Electra also granted 112,676 deferred share units (“DSUs”) to its non-employee directors under the Company’s Deferred Share Unit Plan. The grants further align the interests of the Board of Directors with those of shareholders. The DSUs were granted based on the market price as of September 30, 2026, and will be settled in Common Shares when a director ceases to serve on the Board, subject to the terms of the plan.

The ATM program, initiated in late 2025, provides the Company with flexibility to issue and sell, from time to time, up to US$25 million of its Common Shares from treasury at the Company’s discretion, pursuant to an agreement with H.C. Wainwright & Co., LLC. During the quarter ended September 30, 2026, the Company generated gross proceeds of approximately US$92,000 through the issuance of 150,003 Common Shares under the ATM on the Nasdaq Stock Market LLC at a weighted average price of US$0.6152 per Common Share. The most recent transaction under the ATM was on August 28, 2026. Since inception, the Company’s average issuance price under the ATM is US$0.87 per Common Share. Commissions of approximately US$7,000 were paid in connection with these distributions during the quarter.

About Electra Battery Materials

Electra is a leader in advancing North America’s critical minerals supply chain for lithium-ion batteries. The Company’s primary focus is constructing North America’s only cobalt sulfate refinery, as part of a phased strategy to onshore critical minerals refining and reduce reliance on foreign supply chains. In addition to the Refinery, Electra holds a significant land package in Idaho’s Cobalt Belt, including its Iron Creek project and surrounding properties, positioning the Company as a potential cornerstone for North American cobalt and copper production.

Electra is also advancing black mass recycling opportunities to recover critical materials from end-of-life batteries, while continuing to evaluate growth opportunities in nickel refining and other downstream battery materials. For more information, please visit www.ElectraBMC.com.

Contact

Heather Smiles
Vice President, External Affairs & Corporate Development
Electra Battery Materials
info@ElectraBMC.com
1.416.900.3891

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

ISELIN, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) — Provident Financial Services, Inc. (NYSE: PFS) announced that it expects to release financial results for the quarter ended September 30, 2026 on Wednesday, October 28, 2026 after market close. A copy of the earnings release will be immediately available on the Company’s website, www.Provident.Bank, by going to Investor Relations and clicking on Press Releases.

Representatives of the Company will hold a conference call for investors on October 29, 2026 at 10:00 a.m. (ET) to discuss the Company’s third quarter financial results. Information about the conference call is as follows:

PARTICIPANT DIAL-IN NUMBERS
Meeting ID (required for call access): 178 464 522
North America (Toll-Free): +1 833-461-5787
International (Toll): +1 585-542-9983
All dial-in numbers

Internet access to the call will be available (listen only) at www.Provident.Bank by going to Investor Relations and clicking on Webcast.

A replay of the call will be available beginning at 12:00 noon (ET) on October 29, 2026 at
https://events.q4inc.com/attendee/178464522 and will be archived on the Company’s website for a period of one year.

Provident Financial Services, Inc. is the holding company for Provident Bank. As of June 30, 2026, the Company reported assets of $25.66 billion. The Bank currently operates a network of full-service branches throughout New Jersey, eastern Pennsylvania, and Orange, Queens, and Nassau Counties, New York. The Bank also provides fiduciary and wealth management services through its wholly owned subsidiary, Beacon Trust Company, and insurance services through its wholly owned subsidiary, Provident Protection Plus, Inc.

SOURCE: Provident Financial Services, Inc.
CONTACT: Investor Relations, 1-732-590-9300
Web Site: http://www.Provident.Bank

São Paulo, Oct. 02, 2026 (GLOBE NEWSWIRE) — Marfrig Global Foods S.A. (“MBRF”) (B3: MBRF3; ADR Level 1: MBRFY), through its subsidiary, NBM US Holdings, Inc. (“NBM” or the “Offeror”), announced today that it has terminated its previously announced offer to purchase for cash from each registered holder (each, a “Holder” and, collectively, the “Holders”) any and all of the outstanding 6.625% Senior Notes due 2029 (CUSIP Nos. 62877V AB7; U63768 AB8 / ISIN Nos. US62877VAB71; USU63768AB83) issued by NBM, with US$467,471,000 in aggregate principal amount outstanding (the “Notes” and the “Offer”, respectively), the terms and conditions of which are described in an Offer to Purchase dated September 28, 2026 (the “Offer to Purchase”), as a result of the Financing Condition (as defined below) not having been satisfied.

The Offer was conditioned upon, among other things, the consummation or closing of an offering of one or more issuances of debt securities by MARB BondCo PLC, to be guaranteed by MBRF and the other guarantors thereto, on terms satisfactory to NBM (the “Debt Offering”), in its sole discretion, generating net proceeds in an amount of not less than the maximum aggregate amount to be paid for the Consideration (as defined in the Offer to Purchase) for the Notes tendered and accepted for purchase pursuant to the Offer, plus Accrued Interest from the last interest payment date to, but excluding, the Settlement Date and any applicable additional amounts payable in respect of the Notes (the “Financing Condition”). As of the present date, the Financing Condition has not been satisfied and, therefore, NBM has determined that the Offer has been terminated.

As a result of the termination of the Offer, no Notes will be purchased in the Offer and no Consideration (as defined in the Offer to Purchase) will be paid for any tendered Notes. All Notes previously tendered and not withdrawn will be promptly returned to their respective tendering Holders.

This press release constitutes a formal termination of the Offer, which was made pursuant to the terms and conditions set forth in the Offer to Purchase. The Offeror reserves the right to initiate a new tender offer at a later date, but it is under no obligation to do so. This press release is for informational purposes only and is not an offer to buy, or the solicitation of an offer to sell, any securities.

This press release does not represent an offer to sell securities or a solicitation to buy securities in the United States or in any other country. The Debt Offering has not been and will not be registered with the Securities and Exchange Commission of Brazil (CVM) and also will not be registered under the Securities Act. Consequently, the Notes issued in the Debt Offering are prohibited from being offered or sold in the United States or to U.S. persons without the applicable registration or exemption from registration required under the Securities Act.

This press release is released for disclosure purposes only, in accordance with applicable law. It does not constitute marketing material and should not be interpreted as advertising an offer to sell or soliciting any offer to buy securities issued by the Offeror or any of the Guarantors.

Forward-Looking Statements

This notice includes and references “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may relate to, among other things, the Offeror’s and the Guarantors’ business strategy, goals and expectations concerning their market position, future operations, margins and profitability. Although the Offeror and the Guarantors believe the assumptions upon which these forward-looking statements are based are reasonable, any of these assumptions could prove to be inaccurate and the forward-looking statements based on these assumptions could be incorrect.

The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and trends to differ materially from those made, projected or implied in or by the forward-looking statements depending on a variety of uncertainties or other factors. The Offeror and the Guarantors undertake no obligation to update any of their forward-looking statements.

E-mail: MBRF@dfking.com

PERTH, Australia, Oct. 02, 2026 (GLOBE NEWSWIRE) — Chilwa Minerals Limited, an Australian company (ASX:CHW, NASDAQ:CHWM) (Chilwa or the Company), is pleased to announce the closing of its underwritten public offering. The offering consisted of 625,000 American Depositary Shares (“ADSs“) and warrants to purchase 625,000 ADSs at an offering price of US$5.60 per ADS and accompanying warrant. Each ADS offered represents 10 ordinary shares of Chilwa. The gross proceeds, before deducting underwriter discounts and offering expenses, were US$3.5 million. The warrants have an exercise price of US$5.60 per ADS, are exercisable immediately upon issuance and expire on the fifth anniversary of the original issuance date. The ADSs began trading on the Nasdaq Capital Market under the ticker symbol “CHWM” on October 1, 2026.

In addition, Chilwa granted the underwriter a 45-day option to purchase up to an additional 92,000 ADSs and/or additional 92,000 warrants to purchase up to 92,000 ADSs at the public offering price, which was partially exercised to purchase 92,000 warrants.

Maxim Group LLC acted as sole book-running manager and underwriter for the offering. The Company’s ADS program is administered by BNY.

The Company intends to use the net proceeds from this offering to further its mineral exploration activities, for working capital and other general corporate purposes.

A registration statement on Form F-1 (File No. 333-297336) relating to the public offering was filed with the Securities and Exchange Commission (“SEC”) and became effective on September 29, 2026. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from Maxim Group LLC, 300 Park Ave, 16th Floor, New York, New York 10022. The final prospectus has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov.

This announcement shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For further information contact:
Cadell Buss
Founder and Managing Director
cbuss@chilwaminerals.com.au

About Chilwa Minerals Limited

Chilwa is an Australian mineral exploration company that was formed for the purpose of acquiring the Chilwa Critical Minerals Project (Project) from Luso Global Mining BV. Upon listing on the ASX in July 2023, Chilwa acquired 100% of the issued share capital of Chilwa Minerals Africa Limited, an entity incorporated in Malawi that holds the tenements that comprise the Project. Chilwa’s principal activities are mineral exploration at the Project.

Cautionary Note Regarding Forward-Looking Statements

This announcement contains forward-looking statements about Chilwa and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this announcement, including statements regarding our future results of operations, financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these words or other similar terms or expressions.

The Company has based these forward-looking statements largely on its current expectations and projections about future events and trends that we believe may affect Chilwa’s financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties, other factors and assumptions, including, among other things: our exploration activities and our business operations in general; sufficiency of our cash resources; our ability to profitably extract minerals; our ability to raise additional funding when needed; any statements concerning anticipated regulatory approvals or collaborative arrangements, including our ability to obtain governmental approvals and permits; our operational risks; our ability to remain compliant with the Australian Securities Exchange and Nasdaq’s continuing listing standards; our ability to remediate identified material weaknesses in our internal control over financial reporting; any statement of assumptions underlying any of the foregoing; and other risks and uncertainties, including those listed under “Risk Factors” in the US registration statement file on Form F-1.   These risks are not exhaustive. New risk factors may emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.

Although the Company has attempted to identify important factors that cause results not to be as anticipated, estimated or intended, there can be no assurance that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward looking information. Forward looking information is made as of the date of this announcement and the Company does not undertake to update or revise any forward-looking information which is included herein, except in accordance with applicable securities laws.

HONOLULU, Oct. 02, 2026 (GLOBE NEWSWIRE) — First Hawaiian, Inc. (NASDAQ: FHB) announced today that it plans to release its third quarter 2026 financial results on Friday, October 23, 2026 before the market opens. First Hawaiian will host a conference call to discuss the company’s results on the same day at 1:00 p.m. Eastern Time (7:00 a.m. Hawaii Time).

To access the call by phone, participants will need to click on the following registration link: https://register-conf.media-server.com/register/BI4e0abe37ecf34f5d8bdacfb166cade22, register for the conference call, and then you will receive the dial-in number and a personalized PIN code. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

A live webcast of the conference call, including a slide presentation, will be available at the following link: www.fhb.com/earnings. The archive of the webcast will be available at the same location.

About First Hawaiian

First Hawaiian, Inc. (NASDAQ:FHB) is a bank holding company headquartered in Honolulu, Hawaii. Its principal subsidiary, First Hawaiian Bank, founded in 1858 under the name Bishop & Company, is Hawaii’s oldest and largest financial institution with branch locations throughout Hawaii, Guam and Saipan. The company offers a comprehensive suite of banking services to consumer and commercial customers including deposit products, loans, wealth management, insurance, trust, retirement planning, credit card and merchant processing services. Customers may also access their accounts through ATMs, online and mobile banking channels. For more information about First Hawaiian, Inc., visit www.fhb.com.

Investor Relations Contact:
Kevin Haseyama
(808) 525-6268
khaseyama@fhb.com

Media Contact:
Shari Nishijima
(808) 525-6254
snishijima@fhb.com

  • The US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A is still ongoing. The FDA has not communicated a new timeline for regulatory action on the BLA 
  • The FDA has informed Novo that the ongoing facility remediation activities are the cause for extension of the Agency’s review. The FDA has not identified any deficiencies related to the clinical efficacy or safety data submitted in the denecimig BLA
  • Novo is actively working with the FDA, addressing the Agency’s requests for remediations related to the manufacturing facility. The extended FDA review time for the denecimig BLA has no impact on Novo’s financial outlook for 2026 and pending regulatory decision, Novo aims to launch denecimig in the US in the first half of 2027

Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA. 

Novo submitted a BLA for denecimig for the treatment of haemophilia A in adult and paediatric patients to the US FDA for review in September 2025, with an anticipated regulatory decision in the third quarter of 2026. Following this submission, the FDA performed a pre-license inspection of the manufacturing site and provided feedback. Today, the FDA has informed Novo that the ongoing facility remediation activities are the cause for extension of the Agency’s review.

“Haemophilia A patients should expect more from their standard of care,” said Mike Doustdar, president and CEO of Novo. “As Novo prepares to bring denecimig to market, our ambition is to help make better care something they can count on. Novo is already in the process of addressing the FDA’s requests as efficiently as possible and continuing to work closely with the Agency toward bringing denecimig to patients in the US.”

The Agency has not identified deficiencies related to the clinical efficacy or safety data of denecimig demonstrated in the FRONTIER clinical trial programme. Novo is continuing implementation of the facility remediation activities in response to the FDA’s feedback and is working closely with the Agency to address the outstanding requirements. The feedback on the manufacturing site does not impact other marketed Novo products.

The additional FDA review time does not have an impact on Novo’s financial outlook for 2026. Pending regulatory decision, Novo aims to launch denecimig in the US in the first half of 2027.

About the FRONTIER trials
The FRONTIER clinical programme includes FRONTIER1-5 and investigates denecimig as a prophylactic treatment to prevent bleeding episodes across paediatric and adult populations with haemophilia A, with or without inhibitors.

FRONTIER2, FRONTIER3 and FRONTIER4 formed the basis of the denecimig Marketing Authorisation Application (MAA) submission. FRONTIER2 evaluated denecimig treatment once every month and once every week in adults and adolescents 12 years of age and older; FRONTIER3 evaluated denecimig treatment once every month and once every week in children below the age of 12; FRONTIER4 was an open-label extension trial evaluating the efficacy of denecimig once every two weeks (Q2W) as well as investigating the long-term safety of denecimig across all dosing regimens (once every month, once every two weeks, and once every week) in subjects with haemophilia A, with or without inhibitors.

About denecimig
Denecimig is a FVIIIa mimetic bispecific antibody designed with the aim to deliver once monthly, every two weeks and weekly prophylaxis for people living with haemophilia A, with or without inhibitors. Denecimig, which is administered under the skin, ‘mimics’ the role of FVIIIa by bridging factor IXa and factor X. This action mimics the cofactor function of FVIIIa, which helps restore the body’s thrombin generation capacity, helping blood to clot. On 17 September, denecimig received a positive CHMP opinion and is currently pending marketing approval from the EMA and under review by other regulatory authorities.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.

Publication of inside information pursuant to Market Abuse Regulation, Article 17.

Contacts for further information

Novo Media:  
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com
Novo Investors:  
Michael Novod
+45 3075 6050
nvno@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Max Ung
+45 3077 6414
mxun@novonordisk.com
Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com
Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com

Company announcement No 59 / 2026

Attachment

Following completion of the forensic investigation, company begins notifying impacted individuals

SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) — iRhythm Holdings, Inc. (NASDAQ:IRTC) today provided an update regarding the cybersecurity incident previously disclosed in June 2026. Following completion of the forensic investigation and subsequent review to determine the nature of the impacted data, the company has begun notifying impacted individuals.

As previously disclosed, on or around June 8, 2026, iRhythm detected unauthorized access in certain third-party-hosted business applications. Upon detecting the unauthorized access, iRhythm promptly implemented its incident response plan. As part of the investigation, iRhythm has been working very closely with external cybersecurity professionals experienced in handling these types of incidents. After completing the forensic investigation, iRhythm learned certain data it stores was accessed and downloaded by unauthorized individuals between June 3 and June 8, 2026.

Following the forensic investigation, iRhythm carried out a review to determine the nature of the impacted data. This review concluded the impacted data includes: patient name; patient contact information, including address, email address, and phone number; iRhythm patient account number; iRhythm device serial number; patient insurance number; date of service; and date of birth.

iRhythm has no evidence that any personal information has been or will be used to commit identity theft. However, beginning October 2, 2026, iRhythm began notifying impacted individuals for whom it maintains contact information. Notified individuals have been provided with instructions on best practices to protect their information.

Out of an abundance of caution, those served by iRhythm are encouraged to take steps to protect themselves. This includes protecting themselves against medical identity theft and identity fraud, placing a fraud alert/security freeze on their credit files, obtaining free credit reports, and remaining vigilant in reviewing financial account statements and credit reports for fraudulent or irregular activity on a regular basis.

iRhythm has also established a call center to address questions from impacted individuals. Representatives are available from 8:00 a.m. to 8:00 p.m. Eastern time, Monday through Friday, excluding major U.S. holidays, at 1-844-770-7175.

As iRhythm previously reported, the company has not identified any impact to our products, our clinical or medical device systems, our connections to customers, our manufacturing and distribution operations, patient safety, or our ability to meet patient needs. In addition, iRhythm does not store or retain individual financial account information or payment card information. The company continues to believe, as previously stated in the Current Report on Form 8-K dated June 15, 2026, that the incident is not reasonably likely to have a material impact on the Company’s financial condition or results of operations.

iRhythm is committed to maintaining the privacy and security of personal information in its possession and has taken precautions to safeguard it. iRhythm regularly evaluates and modifies its practices and internal controls to safeguard the security and privacy of the information it maintains and is taking steps to mitigate the risk to individuals impacted by this incident.

Individuals may visit iRhythm’s website https://www.irhythmtech.com/us/en/who-we-are/news-events/notice-of-data-event to learn more about the incident and steps they can take to protect their information.

About iRhythm Holdings
iRhythm is a leading digital health care company with a mission to boldly innovate to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

iRhythm Contacts

Investors Media
Francis Pruell Kassandra Perry
investors@irhythmtech.com mediarelations@irhythmtech.com

Following completion of the forensic investigation, company begins notifying impacted individuals

SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) — iRhythm Holdings, Inc. (NASDAQ:IRTC) today provided an update regarding the cybersecurity incident previously disclosed in June 2026. Following completion of the forensic investigation and subsequent review to determine the nature of the impacted data, the company has begun notifying impacted individuals.

As previously disclosed, on or around June 8, 2026, iRhythm detected unauthorized access in certain third-party-hosted business applications. Upon detecting the unauthorized access, iRhythm promptly implemented its incident response plan. As part of the investigation, iRhythm has been working very closely with external cybersecurity professionals experienced in handling these types of incidents. After completing the forensic investigation, iRhythm learned certain data it stores was accessed and downloaded by unauthorized individuals between June 3 and June 8, 2026.

Following the forensic investigation, iRhythm carried out a review to determine the nature of the impacted data. This review concluded the impacted data includes: patient name; patient contact information, including address, email address, and phone number; iRhythm patient account number; iRhythm device serial number; patient insurance number; date of service; and date of birth.

iRhythm has no evidence that any personal information has been or will be used to commit identity theft. However, beginning October 2, 2026, iRhythm began notifying impacted individuals for whom it maintains contact information. Notified individuals have been provided with instructions on best practices to protect their information.

Out of an abundance of caution, those served by iRhythm are encouraged to take steps to protect themselves. This includes protecting themselves against medical identity theft and identity fraud, placing a fraud alert/security freeze on their credit files, obtaining free credit reports, and remaining vigilant in reviewing financial account statements and credit reports for fraudulent or irregular activity on a regular basis.

iRhythm has also established a call center to address questions from impacted individuals. Representatives are available from 8:00 a.m. to 8:00 p.m. Eastern time, Monday through Friday, excluding major U.S. holidays, at 1-844-770-7175.

As iRhythm previously reported, the company has not identified any impact to our products, our clinical or medical device systems, our connections to customers, our manufacturing and distribution operations, patient safety, or our ability to meet patient needs. In addition, iRhythm does not store or retain individual financial account information or payment card information. The company continues to believe, as previously stated in the Current Report on Form 8-K dated June 15, 2026, that the incident is not reasonably likely to have a material impact on the Company’s financial condition or results of operations.

iRhythm is committed to maintaining the privacy and security of personal information in its possession and has taken precautions to safeguard it. iRhythm regularly evaluates and modifies its practices and internal controls to safeguard the security and privacy of the information it maintains and is taking steps to mitigate the risk to individuals impacted by this incident.

Individuals may visit iRhythm’s website https://www.irhythmtech.com/us/en/who-we-are/news-events/notice-of-data-event to learn more about the incident and steps they can take to protect their information.

About iRhythm Holdings
iRhythm is a leading digital health care company with a mission to boldly innovate to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

iRhythm Contacts

Investors Media
Francis Pruell Kassandra Perry
investors@irhythmtech.com mediarelations@irhythmtech.com

Following completion of the forensic investigation, company begins notifying impacted individuals

SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) — iRhythm Holdings, Inc. (NASDAQ:IRTC) today provided an update regarding the cybersecurity incident previously disclosed in June 2026. Following completion of the forensic investigation and subsequent review to determine the nature of the impacted data, the company has begun notifying impacted individuals.

As previously disclosed, on or around June 8, 2026, iRhythm detected unauthorized access in certain third-party-hosted business applications. Upon detecting the unauthorized access, iRhythm promptly implemented its incident response plan. As part of the investigation, iRhythm has been working very closely with external cybersecurity professionals experienced in handling these types of incidents. After completing the forensic investigation, iRhythm learned certain data it stores was accessed and downloaded by unauthorized individuals between June 3 and June 8, 2026.

Following the forensic investigation, iRhythm carried out a review to determine the nature of the impacted data. This review concluded the impacted data includes: patient name; patient contact information, including address, email address, and phone number; iRhythm patient account number; iRhythm device serial number; patient insurance number; date of service; and date of birth.

iRhythm has no evidence that any personal information has been or will be used to commit identity theft. However, beginning October 2, 2026, iRhythm began notifying impacted individuals for whom it maintains contact information. Notified individuals have been provided with instructions on best practices to protect their information.

Out of an abundance of caution, those served by iRhythm are encouraged to take steps to protect themselves. This includes protecting themselves against medical identity theft and identity fraud, placing a fraud alert/security freeze on their credit files, obtaining free credit reports, and remaining vigilant in reviewing financial account statements and credit reports for fraudulent or irregular activity on a regular basis.

iRhythm has also established a call center to address questions from impacted individuals. Representatives are available from 8:00 a.m. to 8:00 p.m. Eastern time, Monday through Friday, excluding major U.S. holidays, at 1-844-770-7175.

As iRhythm previously reported, the company has not identified any impact to our products, our clinical or medical device systems, our connections to customers, our manufacturing and distribution operations, patient safety, or our ability to meet patient needs. In addition, iRhythm does not store or retain individual financial account information or payment card information. The company continues to believe, as previously stated in the Current Report on Form 8-K dated June 15, 2026, that the incident is not reasonably likely to have a material impact on the Company’s financial condition or results of operations.

iRhythm is committed to maintaining the privacy and security of personal information in its possession and has taken precautions to safeguard it. iRhythm regularly evaluates and modifies its practices and internal controls to safeguard the security and privacy of the information it maintains and is taking steps to mitigate the risk to individuals impacted by this incident.

Individuals may visit iRhythm’s website https://www.irhythmtech.com/us/en/who-we-are/news-events/notice-of-data-event to learn more about the incident and steps they can take to protect their information.

About iRhythm Holdings
iRhythm is a leading digital health care company with a mission to boldly innovate to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

iRhythm Contacts

Investors Media
Francis Pruell Kassandra Perry
investors@irhythmtech.com mediarelations@irhythmtech.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.